Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465450 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
A Phase 2 study, sponsored by Corbus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT02465450 is a Phase 2 study that has completed, run by Corbus Pharmaceuticals. The registered enrollment target is 85 participants.
The verdict
NCT02465450, a Phase 2 study, has completed, sponsored by Corbus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).
Interventions
- OTHER Placebo
- DRUG JBT-101 (lenabasum)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2016-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465450
The ClinicalTrials.gov registry entry for NCT02465450 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02465450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465450 about?
NCT02465450 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).
What is the current status of trial NCT02465450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2015-09-29. Estimated completion is 2016-12-28.
What interventions are being tested in trial NCT02465450?
The interventions under investigation include: Placebo (OTHER), JBT-101 (lenabasum) (DRUG).
Who is sponsoring clinical trial NCT02465450?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.